Health-Canada licensed psychedelics biotech Lucy Scientific Discovery (NASDAQ: LSDI) and not-for-profit psilocybin advocate organization TheraPsil have partnered toward advancing medical psilocybin access and research.

Since 2019, TheraPsil has worked on lawful and compassionate access to psilocybin-assisted therapy for Canadians in need by supporting patients with their applications for federal approval and connecting them with qualified practitioners once approved. 

See also: Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism

The new collaboration is …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.